MedTrace Logo

Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus

NCT05056935 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2021-09-27

No results posted yet for this study

Summary

The purpose of this study is to establish preliminary evidence of the efficacy, safety, and tolerability of LB1148 for the treatment of return of gastrointestinal function and decrease Post-Operative Ileus in subjects undergoing elective bowel resection.

Conditions

  • Ileus

Interventions

DRUG

LB1148

A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.

DRUG

Placebo

A total of 700 mL of placebo will be administered orally as a split dose before surgery.

Sponsors & Collaborators

  • Newsoara Biopharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-09
Primary Completion
2020-07-22
Completion
2020-08-08

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05056935 on ClinicalTrials.gov